Bibliographic record
Abstract
INTRODUCTION: Randomized clinical trials (RCTs) have demonstrated the benefits of chemotherapy for hormone-refractory prostate cancer (HRPC). These data have intensified interest in the use of chemotherapy for non-HRPC. Chemotherapy plus androgen deprivation therapy (ADT) is now under study in a number of RCTs in hormone-naïve patients. MATERIALS AND METHODS: Important data supporting the intuitive, preclinical and clinical rationale for study of chemotherapy plus ADT in non-HRPC were identified and narratively reviewed. RESULTS: There is evidence that chemotherapy can improve survival in HRPC. Chemohormonal therapy reduces recurrence in premenopausal women with estrogen receptor-positive early breast cancer, a group analogous to men with localized prostate cancer. Preclinical data supports earlier use of use of chemotherapy plus ADT simultaneously rather than sequentially. Some RCTs suggest disease control is improved by this approach in non-HRPC. A large single arm trial of docetaxel plus ADT prior to radical prostatectomy has demonstrated safety, feasibility, and evidence of efficacy. CONCLUSIONS: There is sufficient rationale for studying chemotherapy in combination with ADT in non-HRPC. Large scale RCTs investigating this are imminent for men with high-risk localized disease, with biochemical recurrence after local therapy, and with hormone-naïve metastatic disease.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.004 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.014 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".